

RuiRong Yuan, MD, PhD

Dr. RuiRong Yuan currently practices medical oncology at the VA New Jersey Health Care System. She served as Chief Medical Officer for BeiGene as well as Eisai Global Oncology. She was the Head of Americas Oncology Medical Research & Strategy for Eisai. Previously she spent time as Head of Oncology and other therapeutic areas at Daiichi Sankyo where she was responsible for their early and late stage clinical programs in the United States. Prior to this Dr. Yuan was a Senior Global R&D Clinical Leader at Novartis Oncology where she led global teams conducting registrational studies for Afinitor and supported its successful regulatory approval in patients with renal cell carcinoma.

Dr. Yuan is a founding member of CAHON, where she has also previously served as both President and Chairman of the Board of Directors. She earned her medical doctor degrees from Shandong Medical University, China, and The University of Bern, Switzerland, and her post-doctoral fellowship in immunology from the Albert Einstein College of Medicine (AECOM). She is U.S. board-certified in both internal medicine and medical oncology after her clinical oncology and hematology fellowship at Cancer Hospital of Peking Union Medical College, China, and Memorial Sloan Kettering Cancer Center, United States.

More about Ruirong

Dr. RuiRong Yuan is a board certified Medical Oncologist and served as Chief Medical Officer and VP of Eisai Oncology. She also served as Head of multiple therapeutic areas at Daiichi Sankyo and responsible for DSI's late and early clinical programs across multiple therapeutic areas (Oncology, HTN, Metabolism, Pain, Clinical Ops/Biometrics and Business Development-Medical). Before DSI, she was a Senior Global R&D Clinical Leader at Novartis Oncology where she led clinical development teams in conducting Afinitor global registrational studies. Dr. Yuan has had extensive academic clinical practice and research experience as a physician-scientist at top cancer centers in Asian, Europe and the US prior to pharmaceutical industry. She graduated from Shandong Medical University, received her postgraduate training in clinical medical oncology and tumor immunology at the Chinese Academy of Medical Sciences and in molecular biology at Bern University, Switzerland. Before her clinical fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center, Dr. Yuan worked at Albert Einstein College of Medicine as a post-doctoral fellow in immunology followed by a residency in internal medicine. Her Lab focused on translational research in cancer and autoimmune diseases and her special clinical interest was the treatment of patients with solid tumors, especially lymphoma, gastrointestinal malignancies and ovarian cancer. She has authored >30 peer-reviewed original research articles, including publications in Journal Experimental Medicine, Blood, Journal of Immunology, PNAS, British J. Cancer, Cancer Research, Annals of Neurology, Journal of Hematology and Oncology and PLoS ONE. She holds multiple patents related to either cancer treatment or autoimmune disease therapy.

Dr. Yuan is one of the founding members of the Chinese American Hematologist and Oncologist Network (www.cahon.org) and served as its president in 2007-2008. She has been an executive member of the Chinese Society of Clinical Oncology (CSCO) since 2004 and served the ASCO-International Affairs committee (IAC) from July 2006-June 2009. She is the managing editor of the Journal of Hematology & Oncology and serves as an editor for the Journal of Chinese Clinical Oncology.

More about Jiping

Dr. Wang is a surgical oncologist at Brigham and Women's Hospital. He completed a PhD program in Biostatistics at the University of Pittsburgh and gained valuable experience in clinical trial through his role as a biostatistician at National Surgical Adjuvant Breast and Bowel Project (NSABP). He continues to participate in clinical trial activities since joining the faculty of HMS. He also teaches clinical trial courses extensively both in China and at Longwood area. In addition, he has been sitting in the advisory committee for the Ministry of Chinese Science and Technology in the establishment of National Clinical Trial Center. He also designed a phase III clinical trial in evaluating the efficacy of heated intraperitoneum chemotherapy in treating T3 or T4 gastric cancer after radical gastrectomy with D2 lymph nodes dissection.

Dr. Wang is active in educating Harvard Medical School students, BWH/MGH residents. In addition, he has been the HST ICM course proctor for HMS student. He developed teaching video for gastrectomy and D2 lymph node dissection. As the SSAT international committee member, he proposed and assisted the committee to create the video forum: How I do it-gastrectomy with D2 lymph nodes dissection: experts from Asia, Europe, South and North America.

Dr. Wang continues to pursue his research career as well in cancer genomics, particularly in the areas of miRNA biology in colon cancer, Her2 dysregulation in gastric cancer, and genomic landscapes in metastatic diseases.